Mineralys Therapeutics Announces Q3 2024 Results and Updates [Yahoo! Finance]
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics to Participate in Upcoming Investor Conferences